We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Firms With NSAIDs in Pipeline Must Study CV Risks Before Approval, Jenkins Says
Firms With NSAIDs in Pipeline Must Study CV Risks Before Approval, Jenkins Says
July 5, 2005
Pharmaceutical firms developing new nonsteroidal anti-inflammatory drugs (NSAIDs) should conduct long-term trials to test their products for cardiovascular risks, a top FDA official says.